CL2022000027A1 - Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257). - Google Patents

Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257).

Info

Publication number
CL2022000027A1
CL2022000027A1 CL2022000027A CL2022000027A CL2022000027A1 CL 2022000027 A1 CL2022000027 A1 CL 2022000027A1 CL 2022000027 A CL2022000027 A CL 2022000027A CL 2022000027 A CL2022000027 A CL 2022000027A CL 2022000027 A1 CL2022000027 A1 CL 2022000027A1
Authority
CL
Chile
Prior art keywords
antagonist compounds
pcsk9 antagonist
application divisional
divisional
application
Prior art date
Application number
CL2022000027A
Other languages
English (en)
Inventor
Chengwei Wu
Elisabetta Bianchi
Harold B Wood
Hubert B Josien
Thomas Joseph Tucker
Angela Dawn Kerekes
Ling Tong
Abbas M Walji
Anikumar G Nair
Fa-Xiang Ding
Danila Branca
Yusheng Xiong
Sookhee Nicole Ha
Jian Liu
Sobhana Babu Boga
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CL2022000027A1 publication Critical patent/CL2022000027A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

COMPUESTOS ANTAGONISTAS DE PCSK9. (DIVISIONAL DE SOLICITUD 202003257).
CL2022000027A 2018-06-21 2022-01-05 Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257). CL2022000027A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862687913P 2018-06-21 2018-06-21

Publications (1)

Publication Number Publication Date
CL2022000027A1 true CL2022000027A1 (es) 2022-08-19

Family

ID=67263083

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2020003257A CL2020003257A1 (es) 2018-06-21 2020-12-16 Compuestos antagonistas de pcsk9.
CL2022000027A CL2022000027A1 (es) 2018-06-21 2022-01-05 Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2020003257A CL2020003257A1 (es) 2018-06-21 2020-12-16 Compuestos antagonistas de pcsk9.

Country Status (25)

Country Link
US (2) US11427616B2 (es)
EP (1) EP3810626A1 (es)
JP (2) JP7112531B2 (es)
KR (1) KR20210024035A (es)
CN (1) CN112313243A (es)
AR (1) AR115597A1 (es)
AU (2) AU2019290163C1 (es)
BR (1) BR112020025274A8 (es)
CA (1) CA3102629A1 (es)
CL (2) CL2020003257A1 (es)
CO (1) CO2021000456A2 (es)
CR (1) CR20210031A (es)
DO (1) DOP2020000250A (es)
EA (1) EA202190086A1 (es)
EC (1) ECSP21003643A (es)
GE (1) GEP20237506B (es)
IL (1) IL279363A (es)
JO (1) JOP20190150A1 (es)
MA (1) MA52967A (es)
MX (1) MX2020013726A (es)
NI (1) NI202000101A (es)
PE (1) PE20211584A1 (es)
PH (1) PH12020552187A1 (es)
SG (1) SG11202012451WA (es)
WO (1) WO2019246349A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100558932B1 (ko) * 2005-04-21 2006-03-10 주식회사 엠제이스마트 테크놀러지 다공성 세라믹 분리막 제조방법과, 이에 의해 제조되어진 다공성 세라믹 분리막
US9822157B2 (en) 2013-03-15 2017-11-21 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
DK3143037T3 (da) 2014-05-16 2021-09-20 Protagonist Therapeutics Inc Alpha4beta7-integrin-thioether-peptidantagonister
EP3169403B1 (en) 2014-07-17 2024-02-14 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US11753443B2 (en) 2018-02-08 2023-09-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2019246405A1 (en) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Cyclic polypeptides for pcsk9 inhibition
EP3810178A4 (en) 2018-06-21 2022-05-04 Merck Sharp & Dohme Corp. CYCLIC POLYPEPTIDES TO INHIBIT PCSK9
WO2019246387A1 (en) 2018-06-21 2019-12-26 Ra Pharmaceuticals, Inc. Cyclic peptides for pcsk9 inhibition
US11306125B2 (en) 2018-06-21 2022-04-19 Merck Sharp & Dohme Corp. PCSK9 antagonists bicyclo-compounds
US11814444B2 (en) 2018-06-21 2023-11-14 Ra Pharmaceuticals, Inc. Cyclic polypeptides for PCSK9 inhibition
JOP20190150A1 (ar) * 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
WO2021041770A1 (en) * 2019-08-30 2021-03-04 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
US20230144324A1 (en) * 2019-12-20 2023-05-11 Merck Sharp & Dohme Llc Pcsk9 antagonist compounds
JP7441955B2 (ja) 2020-01-15 2024-03-01 ヤンセン バイオテツク，インコーポレーテツド インターロイキン２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用
MX2023005994A (es) 2020-11-20 2023-08-11 Janssen Pharmaceutica Nv Composiciones de inhibidores peptidicos del receptor de interleucina-23.
US11932705B2 (en) 2020-12-18 2024-03-19 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
KR20240050369A (ko) 2021-08-19 2024-04-18 머크 샤프 앤드 돔 엘엘씨 Pcsk9 활성과 관련된 상태를 치료하기 위한 화합물
US20230406885A1 (en) 2022-06-15 2023-12-21 Merck Sharp & Dohme Llc Cyclic peptides for trapping interleukin-1 beta

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393046A (en) 1981-01-30 1983-07-12 Merck & Co., Inc. Combination of thiopeptin and other related sulfur-containing cyclic polypeptide antibiotics with rumen-active diimides to improve ruminant feed efficiency
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
EP0970095B1 (en) 1997-03-07 2003-10-29 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
DE69910045T2 (de) 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
JP2004513076A (ja) 2000-07-25 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療で有用なｎ−置換インドール類
US6852738B2 (en) 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
NZ538031A (en) 2002-08-29 2007-10-26 Merck & Co Inc Indoles having anti-diabetic activity
EP1546142A4 (en) 2002-08-29 2007-10-17 Merck & Co Inc INDOLES HAVING ANTIDIABETIC EFFECT
JP2007504285A (ja) 2003-01-17 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−シクロヘキシルアミノカルボニルベンゼンスルホンアミド誘導体
WO2008063382A2 (en) 2006-11-07 2008-05-29 Merck & Co., Inc. Antagonists of pcsk9
EP2170883A1 (en) 2007-06-28 2010-04-07 Merck Frosst Canada Ltd. Substituted fused pyrimidines as antagonists of gpr105 activity
CN101743616B (zh) 2007-06-28 2012-02-22 株式会社半导体能源研究所 半导体装置的制造方法
US20110301079A1 (en) 2007-09-21 2011-12-08 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Neuromedin u receptor agonists and uses thereof
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2011037791A1 (en) 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonists of pcsk9
CA2813049A1 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
MX2013007497A (es) 2010-12-28 2013-08-01 Cadila Healthcare Ltd Compuestos heterociclicos adecuados para el tratamiento de dislipidemia.
BR112013032667A2 (pt) * 2011-06-20 2017-12-12 Genentech Inc polipeptídeo de ligação a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o polipeptídeo, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito, método de tratamento de disfunção relacionada ao colesterol em um sujeito, método de tratamento de hipercolesterolemia em um sujeito, método de inibição da ligação de pcsk9 a ldlr e método de detecção da proteína pcsk9 em uma amostra
NZ747501A (en) 2011-10-27 2020-05-29 Massachusetts Inst Technology Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres
WO2013138340A1 (en) 2012-03-13 2013-09-19 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
EP2850095B1 (en) 2012-05-17 2019-10-09 RA Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
RU2015142437A (ru) * 2013-03-14 2017-04-27 Дайити Санкио Ко., Лтд Новые связывающие белки для pcsk9
AU2014237312B2 (en) 2013-03-15 2019-03-28 Shifa Biomedical Corporation Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
WO2016119067A1 (en) 2015-01-30 2016-08-04 Pronasci Inc. Peptides derived from human pcsk9 catalytic domain and uses there of for promoting ldl-r activity
EP3442991A4 (en) 2016-04-15 2019-11-20 RA Pharmaceuticals, Inc. RAS-BINDING PEPTIDES AND METHODS OF USE
EP3474875A1 (en) 2016-06-24 2019-05-01 H. Hoffnabb-La Roche Ag Compositions and methods for treating cardiovascular disease
US10577357B2 (en) 2016-09-19 2020-03-03 The Texas A&M University System Inhibitors of LDLR-PCSK9 protein-protein interaction and methods of their use
CN107158002B (zh) * 2017-07-01 2020-06-16 维亚生物科技(上海)有限公司 苄撑巴比妥类化合物在作为pcsk9拮抗剂和降低低密度脂蛋白中的应用
US11814444B2 (en) 2018-06-21 2023-11-14 Ra Pharmaceuticals, Inc. Cyclic polypeptides for PCSK9 inhibition
EP3810178A4 (en) 2018-06-21 2022-05-04 Merck Sharp & Dohme Corp. CYCLIC POLYPEPTIDES TO INHIBIT PCSK9
WO2019246387A1 (en) 2018-06-21 2019-12-26 Ra Pharmaceuticals, Inc. Cyclic peptides for pcsk9 inhibition
WO2019246405A1 (en) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Cyclic polypeptides for pcsk9 inhibition
US11306125B2 (en) 2018-06-21 2022-04-19 Merck Sharp & Dohme Corp. PCSK9 antagonists bicyclo-compounds
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
WO2021041770A1 (en) 2019-08-30 2021-03-04 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds

Also Published As

Publication number Publication date
US20190389909A1 (en) 2019-12-26
PH12020552187A1 (en) 2021-07-26
US11427616B2 (en) 2022-08-30
TW202019950A (zh) 2020-06-01
KR20210024035A (ko) 2021-03-04
EA202190086A1 (ru) 2021-05-18
MX2020013726A (es) 2021-03-02
JP2021522311A (ja) 2021-08-30
JP2022141879A (ja) 2022-09-29
AU2019290163B2 (en) 2022-08-04
US20230159592A1 (en) 2023-05-25
WO2019246349A8 (en) 2021-02-04
SG11202012451WA (en) 2021-01-28
WO2019246349A1 (en) 2019-12-26
EP3810626A1 (en) 2021-04-28
CO2021000456A2 (es) 2021-01-29
MA52967A (fr) 2021-04-28
CN112313243A (zh) 2021-02-02
NI202000101A (es) 2021-05-28
GEP20237506B (en) 2023-05-25
BR112020025274A2 (pt) 2021-03-09
JP7112531B2 (ja) 2022-08-03
ECSP21003643A (es) 2021-02-26
CL2020003257A1 (es) 2021-07-23
PE20211584A1 (es) 2021-08-18
CA3102629A1 (en) 2019-12-26
CR20210031A (es) 2021-02-11
AR115597A1 (es) 2021-02-03
AU2019290163C1 (en) 2022-11-03
IL279363A (en) 2021-01-31
BR112020025274A8 (pt) 2023-02-14
DOP2020000250A (es) 2021-02-28
AU2022259744A1 (en) 2022-12-01
JOP20190150A1 (ar) 2019-12-21
AU2019290163A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
CL2022000027A1 (es) Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257).
CL2021002880S1 (es) Estuche de auriculares. (divisional solicitud 202000595)
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
CL2020000596S1 (es) Auriculares.
CL2022000698A1 (es) Compuestos de anillo fusionado. (divisional de solicitud 202101171)
EA201990615A1 (ru) Пирролобензодиазепиновые конъюгаты
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
EA201992147A1 (ru) Ингибиторы тирозинкиназы брутона
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
EA202092692A1 (ru) Аналоги рапамицина и их применения
EA202190475A1 (ru) Мини-gde для лечения гликогеноза iii типа
CL2019002232S1 (es) Automóvil.
CL2020001201S1 (es) Automóvil.
CL2020000174S1 (es) Automóvil.
CL2021002108A1 (es) Desinfectante endoscopico mejorado
CL2021002736S1 (es) Herramienta eléctrica. (divisional solicitud 201903646)
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.
CL2020003051S1 (es) Interfaz de cargador. (divisional de solicitud 202000568)
CL2019001469S1 (es) Cepillo de dientes.
CL2020000620S1 (es) Cabezal de cepillo de dientes. (divisional solicitud 201900808)
CL2020000618S1 (es) Cabezal de cepillo de dientes. (divisional solicitud 201900807)
CL2020000617S1 (es) Cabezal de cepillo de dientes. (divisional solicitud 201900806)
CL2021002501A1 (es) Compuestos novedosos y métodos de uso de los mismos.
CL2019001470S1 (es) Cepillo de dientes.
CL2019001121S1 (es) Cepillo de dientes.